Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors.
D. Soulieres
Consultant or Advisory Role - OSI Pharmaceuticals; Roche
Honoraria - Roche
J. Wolf
Employment or Leadership Position - OSI Pharmaceuticals
F. A. Shepherd
Honoraria - OSI Pharmaceuticals; Roche
F. Cappuzzo
Consultant or Advisory Role - Roche
Honoraria - Roche
P. A. Bunn
Consultant or Advisory Role - Abraxis BioScience; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Lilly; Novartis; Poniard Pharmaceuticals; Roche; Sanofi
Stock Ownership - Merrimack
Honoraria - Lilly
R. S. Herbst
Consultant or Advisory Role - Genentech
Research Funding - Genentech
F. R. Hirsch
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche
Research Funding - AstraZeneca; OSI Pharmaceuticals; Syndax; Ventana Medical Systems
K. M. Kerr
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Merck; Pfizer; Roche
Honoraria - AstraZeneca; Lilly; Roche
T. Mitsudomi
Honoraria - AstraZeneca; Chugai Pharma
M. S. Tsao
Consultant or Advisory Role - AstraZeneca; Roche
Research Funding - Roche
C. Yang
Consultant or Advisory Role - OSI Pharmaceuticals
Honoraria - Roche
F. C. Richardson
Employment or Leadership Position - OSI Pharmaceuticals
B. Klughammer
Employment or Leadership Position - Roche
B. Wacker
Consultant or Advisory Role - OSI Pharmaceuticals
D. Sternberg
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
A. M. Davies
Employment or Leadership Position - OSI Pharmaceuticals